2022 was a record-breaking year for immuno-oncology approvals

19 July 2023
biotech_research_test_tube_big

The revolution in oncology brought by immunotherapies shows no sign of abating, with a record number of approvals last year.

Research from GlobalData shows that 10 licenses for immuno-oncology products were granted in 2022.

Overall, the number of approvals has increased by 150% between 2014 and 2022, with Bristol-Myers Squibb’s (NYSE: BMY) Yervoy (ipilimumab) the first to get the ball rolling on what has been a transformational approach to treating cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology